Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT study of Savolitinib in healthy volunteers
NCT03258515Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of savolitinib in solid tumor (6 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline-corrected QT interval. Started Sep 2017; status: completed.
02
Drugs
savolitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03258515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258515.